IN2014DN08721A - - Google Patents
Info
- Publication number
- IN2014DN08721A IN2014DN08721A IN8721DEN2014A IN2014DN08721A IN 2014DN08721 A IN2014DN08721 A IN 2014DN08721A IN 8721DEN2014 A IN8721DEN2014 A IN 8721DEN2014A IN 2014DN08721 A IN2014DN08721 A IN 2014DN08721A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- present
- regions
- modified
- contain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261639729P | 2012-04-27 | 2012-04-27 | |
PCT/US2013/038538 WO2013163630A1 (en) | 2012-04-27 | 2013-04-26 | Modified antibody regions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN08721A true IN2014DN08721A (pl) | 2015-05-22 |
Family
ID=49483948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN8721DEN2014 IN2014DN08721A (pl) | 2012-04-27 | 2013-04-26 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20150065690A1 (pl) |
EP (2) | EP3470433A1 (pl) |
JP (1) | JP6470170B2 (pl) |
KR (2) | KR20200037434A (pl) |
CN (1) | CN104428317B (pl) |
AU (3) | AU2013251309B2 (pl) |
BR (1) | BR112014026740B1 (pl) |
CA (1) | CA2871807C (pl) |
HK (1) | HK1207654A1 (pl) |
IN (1) | IN2014DN08721A (pl) |
MX (1) | MX360368B (pl) |
RU (1) | RU2014147741A (pl) |
WO (1) | WO2013163630A1 (pl) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7179400B2 (ja) * | 2014-05-13 | 2022-11-29 | バイオアトラ インコーポレイテッド | 条件的活性型生物学的タンパク質 |
FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
MX2018007089A (es) | 2015-12-14 | 2019-01-30 | Macrogenics Inc | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. |
US11319383B2 (en) * | 2016-03-14 | 2022-05-03 | Universitetet | Oslo | Engineered immunoglobulins with altered FcRn binding |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
BR112021008060A2 (pt) * | 2018-10-31 | 2021-11-23 | Bioatla Inc | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento |
WO2020185632A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
WO2021030303A1 (en) | 2019-08-12 | 2021-02-18 | Voyager Therapeutics, Inc. | High-sensitivity immunoassay for the detection of frataxin in biofluids |
WO2021040736A1 (en) | 2019-08-30 | 2021-03-04 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
JP2023531141A (ja) * | 2020-05-21 | 2023-07-21 | ザイダス・ライフサイエンシーズ・リミテッド | Fcバリアント及びその調製 |
AU2021275499A1 (en) | 2020-05-22 | 2022-11-24 | Formycon Ag | Ace2-fc fusion proteins and uses thereof |
EP4204091A2 (en) | 2020-10-29 | 2023-07-05 | Formycon AG | Ace2 fusion proteins and uses thereof |
JP2024509543A (ja) | 2021-03-03 | 2024-03-04 | フォーマイコン アーゲー | ACE2 Fc融合タンパク質の製剤 |
WO2023094507A1 (en) | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
PT1562972E (pt) * | 2002-10-15 | 2010-11-10 | Facet Biotech Corp | Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese |
AU2003280247A1 (en) | 2002-11-05 | 2004-06-07 | Affinium Pharmaceuticals, Inc. | Essential novel bacterial polypeptides |
US7355008B2 (en) * | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
WO2005047327A2 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
CN101189028B (zh) * | 2004-07-12 | 2013-05-29 | 马克罗基因公司 | 具有变异Fc区的抗体的鉴定和工程化以及使用方法 |
KR100863776B1 (ko) * | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Fc 변이체 |
EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20110123440A1 (en) * | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
DK1919503T3 (en) * | 2005-08-10 | 2014-12-15 | Macrogenics Inc | Identification and preparation of antibodies with variant fc regions and methods of use thereof |
CA2625619A1 (en) * | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
CA2958185C (en) * | 2007-12-26 | 2020-08-25 | Xencor, Inc. | Fc variants with altered binding to fcrn |
US20110081347A1 (en) * | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
CA2750533A1 (en) | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
EP3916011A1 (en) | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
CN103298834A (zh) * | 2010-08-03 | 2013-09-11 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
US8483058B2 (en) | 2010-08-17 | 2013-07-09 | Qualcomm Incorporated | Systems and methods for traffic policing |
WO2013010927A1 (en) | 2011-07-15 | 2013-01-24 | Basell Poliolefine Italia S.R.L. | Polyolefin strap comprising a random copolymer of propylene with 1-hexene |
AU2012313594C1 (en) * | 2011-09-30 | 2018-05-10 | Chugai Seiyaku Kabushiki Kaisha | Ion concentration-dependent binding molecule library |
EP2804952A4 (en) * | 2012-01-19 | 2015-09-09 | Therapeutic Proteins Int Llc | STABILIZATION OF ANTI-CD20 ANTIBODY RITUXIMAB |
-
2013
- 2013-04-26 AU AU2013251309A patent/AU2013251309B2/en active Active
- 2013-04-26 EP EP18209149.6A patent/EP3470433A1/en active Pending
- 2013-04-26 KR KR1020207009090A patent/KR20200037434A/ko not_active Application Discontinuation
- 2013-04-26 KR KR1020147030719A patent/KR20150008082A/ko not_active IP Right Cessation
- 2013-04-26 EP EP13781110.5A patent/EP2841458A4/en not_active Withdrawn
- 2013-04-26 BR BR112014026740-5A patent/BR112014026740B1/pt active IP Right Grant
- 2013-04-26 IN IN8721DEN2014 patent/IN2014DN08721A/en unknown
- 2013-04-26 MX MX2014012978A patent/MX360368B/es active IP Right Grant
- 2013-04-26 CA CA2871807A patent/CA2871807C/en active Active
- 2013-04-26 WO PCT/US2013/038538 patent/WO2013163630A1/en active Application Filing
- 2013-04-26 CN CN201380022401.0A patent/CN104428317B/zh active Active
- 2013-04-26 RU RU2014147741A patent/RU2014147741A/ru unknown
- 2013-04-26 JP JP2015509206A patent/JP6470170B2/ja active Active
- 2013-04-26 US US14/396,851 patent/US20150065690A1/en not_active Abandoned
-
2015
- 2015-08-26 HK HK15108290.3A patent/HK1207654A1/xx unknown
-
2017
- 2017-09-08 AU AU2017225111A patent/AU2017225111B2/en active Active
-
2018
- 2018-03-02 US US15/910,588 patent/US10954288B2/en active Active
-
2019
- 2019-04-01 AU AU2019202229A patent/AU2019202229B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10954288B2 (en) | 2021-03-23 |
KR20150008082A (ko) | 2015-01-21 |
BR112014026740A2 (pt) | 2017-06-27 |
JP6470170B2 (ja) | 2019-02-13 |
MX2014012978A (es) | 2015-02-05 |
MX360368B (es) | 2018-10-29 |
RU2014147741A (ru) | 2016-06-20 |
CA2871807C (en) | 2022-10-04 |
CA2871807A1 (en) | 2013-10-31 |
BR112014026740B1 (pt) | 2022-10-04 |
HK1207654A1 (en) | 2016-02-05 |
CN104428317B (zh) | 2018-08-28 |
AU2013251309A1 (en) | 2014-10-30 |
JP2015515497A (ja) | 2015-05-28 |
EP2841458A1 (en) | 2015-03-04 |
EP3470433A1 (en) | 2019-04-17 |
AU2019202229A1 (en) | 2019-04-18 |
US20180186863A1 (en) | 2018-07-05 |
EP2841458A4 (en) | 2015-09-16 |
AU2013251309B2 (en) | 2017-06-22 |
AU2017225111A1 (en) | 2017-09-28 |
AU2017225111B2 (en) | 2019-01-03 |
CN104428317A (zh) | 2015-03-18 |
KR20200037434A (ko) | 2020-04-08 |
US20150065690A1 (en) | 2015-03-05 |
WO2013163630A1 (en) | 2013-10-31 |
BR112014026740A8 (pt) | 2021-06-15 |
AU2019202229B2 (en) | 2021-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN08721A (pl) | ||
MX2021014955A (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos. | |
MX2022000026A (es) | Anticuerpos para tau. | |
PH12015502565A1 (en) | Anti-transferrin receptor antibodies and methods of use | |
MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
MX2019006902A (es) | Inmunoglobulinas heterodimericas. | |
MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
TN2012000366A1 (en) | Anticoagulant antidotes | |
IN2014DN05885A (pl) | ||
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
MX340555B (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
MX354303B (es) | Anticuerpos de anti-biotina y metodos de uso. | |
MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
TN2013000388A1 (en) | Anticoagulant antidotes | |
MX353951B (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
MX2015010789A (es) | Anticuerpos anti-pcsm. | |
AU345983S (en) | Cosmetic cases and cosmetic kits | |
UA106373C2 (ru) | Применение поллентара как средства фригопротекторного действия |